Combination Therapy with Aminoglycoside ...
Document type :
Article dans une revue scientifique
Permalink :
Title :
Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU
Author(s) :
Benetazzo, Lucie [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Delannoy, Pierre-Yves [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Houard, Marion [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Wallet, Frederic [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lambiotte, Fabien [Auteur]
Centre hospitalier [Valenciennes, Nord]
Vachée, Anne [Auteur]
Batt, Christian [Auteur]
Van Grunderbeeck, Nicolas [Auteur]
Centre Hospitalier de Lens
Nseir, Saad [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Robineau, Olivier [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Meybeck, Agnès [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Centre Hospitalier Gustave Dron [Tourcoing]
Delannoy, Pierre-Yves [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Houard, Marion [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Wallet, Frederic [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lambiotte, Fabien [Auteur]
Centre hospitalier [Valenciennes, Nord]
Vachée, Anne [Auteur]
Batt, Christian [Auteur]
Van Grunderbeeck, Nicolas [Auteur]
Centre Hospitalier de Lens
Nseir, Saad [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Robineau, Olivier [Auteur]

Centre Hospitalier Gustave Dron [Tourcoing]
Meybeck, Agnès [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Journal title :
Antibiotics
Abbreviated title :
Antibiotics
Volume number :
9
Pages :
777
Publisher :
MDPI AG
Publication date :
2020-11-04
ISSN :
2079-6382
English keyword(s) :
antimicrobialcombination
efficacy of combinations
aminoglycoside
bloodstream infections
extended-spectrum β-lactamase producing Enterobacteriaceae
critical care
bacteremia
efficacy of combinations
aminoglycoside
bloodstream infections
extended-spectrum β-lactamase producing Enterobacteriaceae
critical care
bacteremia
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objectives: Evaluation of the efficacy of empirical aminoglycoside in critically ill patients with bloodstream infections caused by extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E BSI). Methods: Patients ...
Show more >Objectives: Evaluation of the efficacy of empirical aminoglycoside in critically ill patients with bloodstream infections caused by extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E BSI). Methods: Patients treated between 2011 and 2018 for ESBL-E BSI in the ICU of six French hospitals were included in a retrospective observational cohort study. The primary endpoint was mortality on day 30. Results: Among 307 patients, 169 (55%) were treated with empirical aminoglycoside. Death rate was 40% (43% with vs. 39% without aminoglycoside, p = 0.55). Factors independently associated with death were age ≥70 years (OR: 2.67; 95% CI: 1.09–6.54, p = 0.03), history of transplantation (OR 5.2; 95% CI: 1.4–19.35, p = 0.01), hospital acquired infection (OR 8.67; 95% CI: 1.74–43.08, p = 0.008), vasoactive drugs >48 h after BSI onset (OR 3.61; 95% CI: 1.62–8.02, p = 0.001), occurrence of acute respiratory distress syndrome (OR 2.42; 95% CI: 1.14–5.16, p = 0.02), or acute renal failure (OR 2.49; 95% CI: 1.14–5.47, p = 0.02). Antibiotherapy appropriateness was more frequent in the aminoglycoside group (91.7% vs. 77%, p = 0.001). Rate of renal impairment was similar in both groups (21% vs. 24%, p = 0.59). Conclusions: In intensive care unit (ICU) patients with ESBL-E BSI, empirical treatment with aminoglycoside was frequent. It demonstrated no impact on mortality, despite increasing treatment appropriateness.Show less >
Show more >Objectives: Evaluation of the efficacy of empirical aminoglycoside in critically ill patients with bloodstream infections caused by extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E BSI). Methods: Patients treated between 2011 and 2018 for ESBL-E BSI in the ICU of six French hospitals were included in a retrospective observational cohort study. The primary endpoint was mortality on day 30. Results: Among 307 patients, 169 (55%) were treated with empirical aminoglycoside. Death rate was 40% (43% with vs. 39% without aminoglycoside, p = 0.55). Factors independently associated with death were age ≥70 years (OR: 2.67; 95% CI: 1.09–6.54, p = 0.03), history of transplantation (OR 5.2; 95% CI: 1.4–19.35, p = 0.01), hospital acquired infection (OR 8.67; 95% CI: 1.74–43.08, p = 0.008), vasoactive drugs >48 h after BSI onset (OR 3.61; 95% CI: 1.62–8.02, p = 0.001), occurrence of acute respiratory distress syndrome (OR 2.42; 95% CI: 1.14–5.16, p = 0.02), or acute renal failure (OR 2.49; 95% CI: 1.14–5.47, p = 0.02). Antibiotherapy appropriateness was more frequent in the aminoglycoside group (91.7% vs. 77%, p = 0.001). Rate of renal impairment was similar in both groups (21% vs. 24%, p = 0.59). Conclusions: In intensive care unit (ICU) patients with ESBL-E BSI, empirical treatment with aminoglycoside was frequent. It demonstrated no impact on mortality, despite increasing treatment appropriateness.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CNRS
CNRS
Collections :
Research team(s) :
Glycobiology in fungal Pathogenesis and Clinical Applications
Submission date :
2021-07-15T08:58:20Z
2021-07-15T08:59:07Z
2021-07-16T10:23:29Z
2021-07-15T08:59:07Z
2021-07-16T10:23:29Z
Files
- antibiotics-09-00777.pdf
- Version éditeur
- Open access
- Access the document